Literature DB >> 19831737

Comparison of immunopathology and locomotor recovery in C57BL/6, BUB/BnJ, and NOD-SCID mice after contusion spinal cord injury.

Sabina Luchetti1, Kevin D Beck, Manuel D Galvan, Richard Silva, Brian J Cummings, Aileen J Anderson.   

Abstract

Studies of cell transplantation therapeutics in animal models of traumatic spinal cord injury (SCI) are often hampered by partial or complete rejection of the graft by the host. Pharmacological immunosuppression is rarely sufficient to prevent rejection. Further, the immunological niche created by both the host immune response and immunosuppressant drugs could hypothetically influence the proliferation, differentiation, and fate of transplanted progenitor/stem cells. To avoid these confounds, we have previously used the constitutively immunodeficient non-obese diabetic severe combined immunodeficient (NOD-SCID) mouse as a model for transplantation studies following SCI. In the current study, we compare behavioral and histological recovery in NOD-SCID, C57BL/6, and BUB/BnJ mice of both sexes to better facilitate interpretation of data from studies using NOD-SCID mice. Of the strains examined, NOD-SCID mice exhibited the greatest locomotor recovery in the open field; no sex differences were detected in locomotor recovery in any of the strains. Stereologic estimation of the number of infiltrated neutrophils showed more cells in C57BL/6 mice than NOD-SCID mice, with BUB/BnJ mice having an intermediate number. The volume of macrophages/microglia did not differ between strains or sexes, though more rostral-caudal spreading was observed in C57BL/6 and BUB/BnJ than NOD-SCID mice. No significant differences were detected in lesion volume. Taken together these findings demonstrate that relative to other strains, NOD-SCID mice have both similar primary lesion volume and cellular inflammatory parameters after SCI, and support the applicability of the model for neurotransplantation studies.

Entities:  

Mesh:

Year:  2010        PMID: 19831737      PMCID: PMC2834443          DOI: 10.1089/neu.2009.0930

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  85 in total

1.  Long-term changes in the molecular composition of the glial scar and progressive increase of serotoninergic fibre sprouting after hemisection of the mouse spinal cord.

Authors:  Emeline Camand; Marie-Pierre Morel; Andréas Faissner; Constantino Sotelo; Isabelle Dusart
Journal:  Eur J Neurosci       Date:  2004-09       Impact factor: 3.386

2.  Anti-Nogo-A antibody treatment enhances sprouting of corticospinal axons rostral to a unilateral cervical spinal cord lesion in adult macaque monkey.

Authors:  Patrick Freund; Thierry Wannier; Eric Schmidlin; Jocelyne Bloch; Anis Mir; Martin E Schwab; Eric M Rouiller
Journal:  J Comp Neurol       Date:  2007-06-01       Impact factor: 3.215

3.  IL-4 deficiency prevents eosinophilic rejection and uncovers a role for neutrophils in the rejection of MHC class II disparate skin grafts.

Authors:  Murielle Surquin; Alain Le Moine; Véronique Flamand; Katia Rombaut; François-Xavier Demoor; Isabelle Salmon; Michel Goldman; Daniel Abramowicz
Journal:  Transplantation       Date:  2005-11-27       Impact factor: 4.939

4.  Differences in the cerebrovascular anatomy of C57black/6 and SV129 mice.

Authors:  K Maeda; R Hata; K A Hossmann
Journal:  Neuroreport       Date:  1998-05-11       Impact factor: 1.837

5.  Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains.

Authors:  D Michele Basso; Lesley C Fisher; Aileen J Anderson; Lyn B Jakeman; Dana M McTigue; Phillip G Popovich
Journal:  J Neurotrauma       Date:  2006-05       Impact factor: 5.269

6.  Complement in BuB/BnJ mice revisited: serum C3 levels and complement opsonic activity are not elevated.

Authors:  Inga Osmers; Alexander J Szalai; Andrea J Tenner; Scott R Barnum
Journal:  Mol Immunol       Date:  2005-11-28       Impact factor: 4.407

7.  Mouse strains with typical mammalian levels of complement activity.

Authors:  G L Ong; M J Mattes
Journal:  J Immunol Methods       Date:  1989-12-20       Impact factor: 2.303

8.  Interleukin-1beta mediates proliferation and differentiation of multipotent neural precursor cells through the activation of SAPK/JNK pathway.

Authors:  Xiaofei Wang; Saili Fu; Yanxia Wang; Panpan Yu; Jianguo Hu; Wenli Gu; Xiao-Ming Xu; Peihua Lu
Journal:  Mol Cell Neurosci       Date:  2007-07-24       Impact factor: 4.314

9.  Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts.

Authors:  Rutger-Jan Swijnenburg; Sonja Schrepfer; Johannes A Govaert; Feng Cao; Katie Ransohoff; Ahmad Y Sheikh; Munif Haddad; Andrew J Connolly; Mark M Davis; Robert C Robbins; Joseph C Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-26       Impact factor: 11.205

10.  Female TBI patients recover better than males.

Authors:  Z Groswasser; M Cohen; O Keren
Journal:  Brain Inj       Date:  1998-09       Impact factor: 2.311

View more
  19 in total

1.  Achieving stable human stem cell engraftment and survival in the CNS: is the future of regenerative medicine immunodeficient?

Authors:  Aileen J Anderson; Daniel L Haus; Mitra J Hooshmand; Harvey Perez; Christopher J Sontag; Brian J Cummings
Journal:  Regen Med       Date:  2011-05       Impact factor: 3.806

2.  Systemic Neutrophil Depletion Modulates the Migration and Fate of Transplanted Human Neural Stem Cells to Rescue Functional Repair.

Authors:  Hal X Nguyen; Mitra J Hooshmand; Hirokazu Saiwai; Jake Maddox; Arjang Salehi; Anita Lakatos; Rebecca A Nishi; Desiree Salazar; Nobuko Uchida; Aileen J Anderson
Journal:  J Neurosci       Date:  2017-08-28       Impact factor: 6.167

Review 3.  The Biology of Regeneration Failure and Success After Spinal Cord Injury.

Authors:  Amanda Phuong Tran; Philippa Mary Warren; Jerry Silver
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

4.  Neutrophils Induce Astroglial Differentiation and Migration of Human Neural Stem Cells via C1q and C3a Synthesis.

Authors:  Mitra J Hooshmand; Hal X Nguyen; Katja M Piltti; Francisca Benavente; Samuel Hong; Lisa Flanagan; Nobuko Uchida; Brian J Cummings; Aileen J Anderson
Journal:  J Immunol       Date:  2017-07-07       Impact factor: 5.422

5.  Traumatic spinal cord injury in mice with human immune systems.

Authors:  Randall S Carpenter; Kristina A Kigerl; Jessica M Marbourg; Andrew D Gaudet; Devra Huey; Stefan Niewiesk; Phillip G Popovich
Journal:  Exp Neurol       Date:  2015-07-17       Impact factor: 5.330

Review 6.  Hormonal therapy in traumatic spinal cord injury.

Authors:  Parker E Ludwig; Arun A Patil; Andrea J Chamczuk; Devendra K Agrawal
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

7.  miR-155 Deletion in Mice Overcomes Neuron-Intrinsic and Neuron-Extrinsic Barriers to Spinal Cord Repair.

Authors:  Andrew D Gaudet; Shweta Mandrekar-Colucci; Jodie C E Hall; David R Sweet; Philipp J Schmitt; Xinyang Xu; Zhen Guan; Xiaokui Mo; Mireia Guerau-de-Arellano; Phillip G Popovich
Journal:  J Neurosci       Date:  2016-08-10       Impact factor: 6.167

8.  Sexual dimorphism in neurological function after SCI is associated with disrupted neuroinflammation in both injured spinal cord and brain.

Authors:  Yun Li; Rodney M Ritzel; Zhuofan Lei; Tuoxin Cao; Junyun He; Alan I Faden; Junfang Wu
Journal:  Brain Behav Immun       Date:  2021-12-23       Impact factor: 7.217

9.  Human neural stem cells differentiate and promote locomotor recovery in an early chronic spinal cord injury NOD-scid mouse model.

Authors:  Desirée L Salazar; Nobuko Uchida; Frank P T Hamers; Brian J Cummings; Aileen J Anderson
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

10.  Cytosolic phospholipase A2 protein as a novel therapeutic target for spinal cord injury.

Authors:  Nai-Kui Liu; Ling-Xiao Deng; Yi Ping Zhang; Qing-Bo Lu; Xiao-Fei Wang; Jian-Guo Hu; Eddie Oakes; Joseph V Bonventre; Christopher B Shields; Xiao-Ming Xu
Journal:  Ann Neurol       Date:  2014-04-02       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.